Anal High-grade Squamous Intraepithelial Lesion
Conditions
Keywords
Anal cytology, Human papillomavirus(HPV), High resolution anoscopy (HRA)
Brief summary
This the propose to use the Multiphase Optimization Strategy Trial (MOST) design to identify an anal HSIL screening algorithm which is most suitable in terms of effectiveness, efficiency, and economy. Specifically, The Investigators will use a factorial design as the main strategy in the MOST, as this allows the evaluation of multiple intervention components that are candidates for ultimate inclusion in the algorithm. The Investigators will then implement the most suitable anal HSIL screening algorithm in the clinic, using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework to guide its design, implementation, and evaluation. An interrupted time series will be used to compare anal HSIL screening uptake among men who have sex with men clients in the clinic, prior to and after the implementation of the new anal HSIL screening algorithm, and mixed-methods approaches will be used to evaluate components of the RE-AIM framework.
Detailed description
I. PREPARATION PHASE Purpose To lay groundwork for optimization of anal high-grade squamous intraepithelial lesion screening algorithm for MSM, and identify which test and component(s) should be included in the anal HSIL screening algorithm. II. OPTIMIZATION PHASE Purpose To form an anal high-grade squamous intraepithelial lesion screening algorithm that meets the optimization criteria. III. EVALUATION PHASE Purpose To establish whether the optimized anal high-grade squamous intraepithelial lesion screening algorithm has a statistically significant effect on service uptake among MSM compared to the standard of care.
Interventions
PROCEDUREOPTIMIZATION PHASE
The goal of the optimization phase of MOST is to identify the most promising combination of experimental components in changing an outcome given a set of environmental constraints. Looking at effectiveness, efficiency, economy, and scalability criteria, we will focus on the proportion of anal HSIL identified (effectiveness), unit cost (efficiency and economy), and accumulating cost to the client over a 12-month period (economy). Meeting these criteria will likely imply scalability. The most appropriate anal HSIL screening algorithm would ideally be one which could \- identify anal HSIL in at least 20% of HIV-positive MSM and 10% of HIV-negative MSM at baseline and
Sponsors
Institute of HIV Research and Innovation Foundation, Thailand
National Institutes of Health (NIH)
amfAR, The Foundation for AIDS Research
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Clients for MSM and TGW: * Thai nationality, men with self-identifies as MSM and/or TGW * HIV-positive MSM/TGW aged 30 years or older or * HIV-negative MSM/TGW aged 40 years or older Clinic staff: \- Has worked in the study clinic during phase III Government stakeholders: \- Involved in health policy development in Thailand
Exclusion criteria
Clients for MSM and TGW: * Unable to perform any study procedures, or unable to commit to attend all study visits. * Had Anal cancer lesion at enrollment visit, this exclusion for participation in phase II study. Clinic staff: \- Not willing to participate in the evaluation Government stakeholders: \- Not willing to participate in the evaluation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identify new cases of anal HSIL by Anal HSIL screening algorithm | 18 months | identify anal HSIL in at least 20% of HIV-positive MSM/TGW and 10% of HIV-negative MSM/TGW within visit schedule. |
| Compare anal HSIL screening method to new anal HSIL screening method algorithm | 24 months | Evaluate anal HSIL screening method uptake among MSM/TGW clients in the clinic compare to the implementation of the new anal HSIL screening method algorithm. |
Countries
Thailand
Contacts
PRINCIPAL_INVESTIGATORNittaya Phanuphak, MD,PhD.
Institute of HIV Research and Innovation
Outcome results
None listed